MN SF4500 | 2021-2022 | 92nd Legislature

Status

Spectrum: Moderate Partisan Bill (Democrat 4-1)
Status: Introduced on April 19 2022 - 25% progression, died in committee
Action: 2022-04-19 - Referred to State Government Finance and Policy and Elections
Pending: Senate State Government Finance and Policy and Elections Committee
Text: Latest bill text (Introduced) [PDF]

Summary

Office of Cannabis Derivatives establishment

Tracking Information

Register now for our free OneVote public service or GAITS Pro trial account and you can begin tracking this and other legislation, all driven by the real-time data of the LegiScan API. Providing tools allowing you to research pending legislation, stay informed with email alerts, content feeds, and share dynamic reports. Use our new PolitiCorps to join with friends and collegaues to monitor & discuss bills through the process.

Monitor Legislation or view this same bill number from multiple sessions or take advantage of our national legislative search.

Title

Office of Cannabis Derivatives establishment

Sponsors


History

DateChamberAction
2022-04-19SenateReferred to State Government Finance and Policy and Elections
2022-04-19SenateIntroduction and first reading

Minnesota State Sources


Bill Comments

LegiScan Search

View Top 50 Searches

Select area of search.
Find an exact bill number.
Search bill text and data. [help]
Reset

LegiScan Trends

View Top 50 National

CA SB1174 Elections: voter identification.
NH SB393 Relative to making an appropriation to the department of environmental...
MA H4193 To improve quality and oversight of long-term care
AL HB7 Illegal immigration; procedures for arrest, detention, transportation of...
IL SB1479 INS-REGULATORY EXAM/COMPLIANCE
MA H4508 Authorizing the city of Watertown to place municipal charge liens on certain...
IL HB4447 INFO PROTECTION-REGISTRATION
MI HB4718 Criminal procedure: defenses; sexual orientation or gender identity of...
PA HB1490 Further providing for definitions, for regulation of the practice of acupuncture,...
MA S2520 Relative to pharmaceutical access, costs and transparency
feedback